{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:39:47Z","timestamp":1790314787257,"version":"4.1.0"},"reference-count":52,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Eravacycline (TP-434 or 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline) is a novel fluorocycline that was evaluated for antimicrobial activity against panels of recently isolated aerobic and anaerobic Gram-negative and Gram-positive bacteria. Eravacycline showed potent broad-spectrum activity against 90% of the isolates (MIC\n            <jats:sub>90<\/jats:sub>\n            ) in each panel at concentrations ranging from \u22640.008 to 2 \u03bcg\/ml for all species panels except those of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Pseudomonas aeruginosa<\/jats:named-content>\n            and\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Burkholderia cenocepacia<\/jats:named-content>\n            (MIC\n            <jats:sub>90<\/jats:sub>\n            values of 32 \u03bcg\/ml for both organisms). The antibacterial activity of eravacycline was minimally affected by expression of tetracycline-specific efflux and ribosomal protection mechanisms in clinical isolates. Furthermore, eravacycline was active against multidrug-resistant bacteria, including those expressing extended-spectrum \u03b2-lactamases and mechanisms conferring resistance to other classes of antibiotics, including carbapenem resistance. Eravacycline has the potential to be a promising new intravenous (i.v.)\/oral antibiotic for the empirical treatment of complicated hospital\/health care infections and moderate-to-severe community-acquired infections.\n          <\/jats:p>","DOI":"10.1128\/aac.01288-13","type":"journal-article","created":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T04:14:23Z","timestamp":1377576863000},"page":"5548-5558","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":229,"title":["Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens"],"prefix":"10.1128","volume":"57","author":[{"given":"J. A.","family":"Sutcliffe","sequence":"first","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fyfe","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. H.","family":"Grossman","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-80"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.12.1430"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.11.009"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004129"},{"key":"e_1_3_2_7_2","volume-title":"New carbapenem-resistant Enterobacteriaceae warrant additional action by healthcare providers","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. 14 February 2013, posting date. New carbapenem-resistant Enterobacteriaceae warrant additional action by healthcare providers. Centers for Disease Control and Prevention, Atlanta, GA. http:\/\/emergency.cdc.gov\/HAN\/han00341.asp."},{"key":"e_1_3_2_8_2","first-page":"1, 56\u201358","article-title":"Resistant bugs necessitate tougher tactics","volume":"30","author":"Liszewskik K","year":"2010","unstructured":"LiszewskikK. 2010. Resistant bugs necessitate tougher tactics. Genet. Eng. Biotechnol. News 30:1, 56\u201358.","journal-title":"Genet. Eng. Biotechnol. News"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/605630"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir153"},{"key":"e_1_3_2_11_2","volume-title":"World Health Day 2011: policy briefs","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. 2011. World Health Day 2011: policy briefs. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/world-health-day\/2011\/policybriefs\/en\/index.html."},{"key":"e_1_3_2_12_2","first-page":"165","article-title":"Vital signs: carbapenem-resistant Enterobacteriaceae","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. 2013. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb. Mortal. Wkly. Rep. 62:165\u2013170.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2013.00048"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00126-09"},{"key":"e_1_3_2_15_2","volume-title":"The novel broad-spectrum fluorocycline TP-434 is active against MDR gram-negative pathogens","author":"Fyfe C","year":"2011","unstructured":"FyfeCGrossmanTO'BrienWAchornCSutcliffeJ. 2011. The novel broad-spectrum fluorocycline TP-434 is active against MDR gram-negative pathogens, abstr P-1149. Abstr. 21st Eur. Congr. Clin. Microbiol. Infect. Dis.\/27th Int. Congr. Chemother., Milan, Italy, 7 to 10 May 2011."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm201465w"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06187-11"},{"key":"e_1_3_2_18_2","volume-title":"In vitro activity of fluorocycline TP-434 against panels of recent bacterial clinical isolates","author":"Sutcliffe J","year":"2010","unstructured":"SutcliffeJO'BrienWAchornCAppelbaumPPillarCZurenkoG. 2010. In vitro activity of fluorocycline TP-434 against panels of recent bacterial clinical isolates, abstr F1-2158. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., 12 to 15 September 2010."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm201467r"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1109755"},{"key":"e_1_3_2_21_2","volume-title":"Efficacy and safety of TP-434 (eravacycline) versus ertapenem in complicated intra-abdominal infection (cIAI)","author":"Solomkin JS","year":"2012","unstructured":"SolomkinJSCesnauskasGRameshMWalpoleSSutcliffeJHornP. 2012. Efficacy and safety of TP-434 (eravacycline) versus ertapenem in complicated intra-abdominal infection (cIAI), abstr L1-1647a. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 9 to 12 September 2012."},{"key":"e_1_3_2_22_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"CLSI","year":"2012","unstructured":"CLSI. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M07-A9. CLSI, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_23_2","volume-title":"Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement","author":"CLSI","year":"2012","unstructured":"CLSI. 2012. Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement. CLSI document M100-S22. CLSI, Wayne, PA."},{"key":"e_1_3_2_24_2","volume-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard","author":"CLSI","year":"2012","unstructured":"CLSI. 2012. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 8th ed. CLSI document M11-A8. CLSI, Wayne, PA.","edition":"8"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.12.2650"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1857-1864.2005"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp498"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.6.2153-2162.2002"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.micro.112408.134309"},{"key":"e_1_3_2_30_2","volume-title":"Tygacil (tigecycline) for injection for intravenous use, package insert, revised","author":"Wyeth Pharmaceuticals, Inc","year":"2012","unstructured":"Wyeth Pharmaceuticals, Inc. November 2012. Tygacil (tigecycline) for injection for intravenous use, package insert, revised. Wyeth Pharmaceuticals, Inc, Philadelphia, PA."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.172.12.6942-6949.1990"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1865-1871.2005"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis275"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1901.120310"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1301.060716"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000251496.61520.75"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.6.5.751"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03658.x"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1586\/erp.10.49"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904124"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1086\/661597"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq191"},{"key":"e_1_3_2_43_2","volume-title":"TP-434 has potential to treat complicated urinary tract infections (cUTI)","author":"Sutcliffe J","year":"2011","unstructured":"SutcliffeJGrossmanTRonnMXiaoXLeightonA. 2011. TP-434 has potential to treat complicated urinary tract infections (cUTI), abstr F1-1858. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17 to 20 September 2011."},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00404-09"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.03.012"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1086\/663714"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767160-00005"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e3283553441"},{"key":"e_1_3_2_49_2","volume-title":"Pharmacokinetics, safety and tolerability of a novel fluorocycline, TP-434, following multiple dose oral administration with and without food","author":"Horn PT","year":"2011","unstructured":"HornPTSutcliffeJWalpoleSMLeightonA. 2011. Pharmacokinetics, safety and tolerability of a novel fluorocycline, TP-434, following multiple dose oral administration with and without food, abstr 603. Abstr. Infect. Dis. Soc. Am. 49th Annu. Meet., Boston, MA, 20 to 23 October 2011."},{"key":"e_1_3_2_50_2","volume-title":"Population pharmacokinetic modeling of TP-434, a novel fluorocycline, following single and multiple dose administration","author":"Seng Yue C","year":"2010","unstructured":"Seng YueCSutcliffeJAColucciPSprengerCRDucharmeMP. 2010. Population pharmacokinetic modeling of TP-434, a novel fluorocycline, following single and multiple dose administration, abstr A1-028. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., 12 to 15 September 2010."},{"key":"e_1_3_2_51_2","volume-title":"Broad-spectrum fluorocycline TP-434 has oral bioavailability in humans","author":"Leighton A","year":"2011","unstructured":"LeightonAZupanetsIBezuglaNPlamondonLMacdonaldGSutcliffeJ. 2011. Broad-spectrum fluorocycline TP-434 has oral bioavailability in humans, abstr P-1509. Abstr. 21st Eur. Congr. Clin. Microbiol. Infect. Dis.\/27th Int. Congr. Chemother., Milan, Italy, 7 to 10 May 2011."},{"key":"e_1_3_2_52_2","volume-title":"Phase 1 single and multiple ascending dose studies of a broad-spectrum fluorocycline, TP-434","author":"Sutcliffe J","year":"2010","unstructured":"SutcliffeJRonnMLeightonASprengerC. 2010. Phase 1 single and multiple ascending dose studies of a broad-spectrum fluorocycline, TP-434, abstr A1-027. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., 12 to 15 September 2010."},{"key":"e_1_3_2_53_2","volume-title":"Characterization of baseline pathogens and microbiological eradication in a phase 2 trial for treatment of complicated intra-abdominal infections comparing eravacycline (TP-434) to ertapenem","author":"Fyfe C","year":"2013","unstructured":"FyfeCDeaneJGrossmanTHornPMooreGSahmDStudenyJWalpoleSSutcliffeJ. 2013. Characterization of baseline pathogens and microbiological eradication in a phase 2 trial for treatment of complicated intra-abdominal infections comparing eravacycline (TP-434) to ertapenem, abstr O277. Abstr. 23rd Eur. Congr. Clin. Microbiol. Infect. Dis., Berlin, Germany, 27 to 30 April 2013."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01288-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01288-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:34:42Z","timestamp":1645482882000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01288-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1128\/AAC.01288-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.01288-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"2013-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-08-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-10-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}